On September 27, the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association released the “2024 Shenzhen Top 500 Enterprises” list. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 149th, by virtue of its outstanding operational performance, social contributions, etc. Additionally, Shenzhen Kangzhe was also included in the “2024 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2024 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500.”
CMS has been deeply rooted in the Chinese pharmaceutical market for over 30 years, developing into a platform company linking pharmaceutical innovation and commercialization. Shenzhen Kangzhe’s inclusion in the “Shenzhen Top 500 Enterprises” for the fourth time not only affirms the Group’s long-term strategic focus on specialty therapeutic fields and its success in providing differentiated products and services, but also motivates the Group to pursue innovation and transformation from a strategic level, further exploring innovative growth momentum to achieve sustainable, high-quality development.